Trial Profile

A Phase 3 Trial of the Efficacy and Safety of Bardoxolone Methyl in Patients With Autosomal Dominant Polycystic Kidney Disease

Status: Discontinued

Phase of Trial: Phase III

Latest Information Update: 09 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bardoxolone methyl (Primary)
Indications Autosomal dominant polycystic kidney disease
Focus Adverse reactions; Registrational; Therapeutic Use
Acronyms FALCON
Sponsors Biogen; Reata Pharmaceuticals

Most Recent Events

12 Jul 2023 This trial has been completed in Germany (Date of the global end of the trial: 06-Jul-2023), according to the European Clinical Trials Database record.
11 Jul 2023 This trial has been completed in France, according to European Clinical Trials Database record.
04 Jul 2023 This trial has been Discontinued in Spain, according to European Clinical Trials Database record.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com